Advertisements



NJ firm advancing drug for pancreatic, hard-to-treat cancers

Earlier this year a Newark, N.J.–based holding company led by longtime telecom entrepreneur Howard Jonas upped its investment in a pharmaceutical company developing drugs to treat rare and... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkMar 15th, 2019

NJ firm advancing drug for pancreatic, hard-to-treat cancers

Earlier this year a Newark, N.J.–based holding company led by longtime telecom entrepreneur Howard Jonas upped its investment in a pharmaceutical company developing drugs to treat rare and... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkMar 15th, 2019

Google’s AI is now better than doctors at spotting breast cancer

Cancer researchers are constantly advancing the technology that doctors use to screen for, detect, and treat all kinds of cancers, and the survivability prospects have greatly improved over the past few decades......»»

Category: topSource: moneycentralOct 16th, 2018

Novartis Gambles $8.7 Billion on Gene-Therapy Firm

Swiss drug maker Novartis has agreed to acquire U.S.-based AveXis for $8.7 billion in cash. AveXis is developing a gene-therapy to treat an inherited disease to treat the leading cause of........»»

Category: blogSource: 247wallstApr 9th, 2018

FDA says Nutra Pharma illegally markets unapproved products claiming to treat addiction and chronic pain

The Food and Drug Administration said on Tuesday it had posted a warning letter to Nutra Pharma Corp. for illegally mark.....»»

Category: topSource: marketwatch48 min. ago

Mylan voluntarily recalls two lots of its levoleucovorin injection

Mylan N.V. said on Monday that it is voluntarily recalling two lots of its levoleucovorin injection due to the discovery of foreign particulates in the drug. Levoleucovorin is used to reduce harmful effects of methotrexate, a medication used to treat p.....»»

Category: topSource: marketwatch20 hr. 18 min. ago

The Wall Street Journal: Adamis Pharma stock jumps after FDA agrees to review injectable opioid-overdose treatment

Adamis Pharmaceuticals Corp. said the U.S. Food and Drug Administration has accepted for review its New Drug Application for a naloxone injection product used to treat opioid overdoses......»»

Category: topSource: marketwatchMar 14th, 2019

FDA approves 1st immunotherapy drug to treat breast cancer

The U.S. Food and Drug Administration has approved the first immunotherapy drug for breast cancer......»»

Category: topSource: foxnewsMar 8th, 2019

Can Tonix Regain Its Former Glory With New Neurodegenerative Dysfunction Drug?

Tonix Pharma shares spiked on Friday after the firm announced that it received a patent from the European Patent Office for its “Method for Treating Neurodegenerative Dysfunction.”.....»»

Category: blogSource: 247wallstMar 8th, 2019

Horizon Pharma Stock Goes Vertical After Positive Eye Disease Drug Results

Horizon Pharma's stock price skyrockets after the Dublin-based biotech reports positive results for a new drug to treat a rare but devastating eye disease......»»

Category: topSource: moneycentralFeb 28th, 2019

Trump Eases Off Hard Deadline for China Tariffs

President Trump gave his firmest indication yet that the U.S. may not increase tariffs on Chinese goods on March 1, as scheduled, despite statements by his top trade official that the U.S. should stick to a firm deadline......»»

Category: asiaSource: wsjFeb 20th, 2019

Cannabis retailers hit hard in Cuomo’s tax idea

Sooner or later, it was sure to be part of the conversation. As Gov. Andrew Cuomo continued his push in January to legalize cannabis for recreational adult use, he outlined a three-tier structure on how the drug would be taxed. “We have to do i.....»»

Category: topSource: bizjournalsFeb 18th, 2019

FDA Challenges Supplement Makers" Marketing Claims

The Food and Drug Administration sent warning letters accusing 17 nutritional-supplement makers of selling more than 58 products with improper claims that they can prevent, treat or cure serious diseases......»»

Category: smallbizSource: wsjFeb 12th, 2019

These companies are illegally selling products claiming to treat Alzheimer’s

The U.S. Food and Drug Administration has taken action against 17 companies illegally selling more than 58 products, many as dietary supplements, that claim to treat Alzheimer’s disease and other serious diseases and health conditions......»»

Category: topSource: marketwatchFeb 11th, 2019

Regeneron, Sanofi to offer new Praluent high cholesterol drug options at 60% discount

Regeneron Pharmaceuticals Inc. and Sanofi said Monday that Praluent, used to treat high cholesterol, will be available at about 60% less than original prices. The new reduced U.S. list price of $5,850 a year will be for both 75 milligra.....»»

Category: topSource: marketwatchFeb 11th, 2019

FDA takes actions against 17 companies selling products illegally claiming to treat Alzheimer"s

The Food and Drug Administration said Monday it has taken action against 17 companies that are "illegally .....»»

Category: topSource: marketwatchFeb 11th, 2019

Blood-Pressure Medicine Will Be First Product for New Generic Drug Venture

A new venture to supply generic medicines says it will start with blood-pressure drug metoprolol, which has been hard to get......»»

Category: smallbizSource: wsjFeb 5th, 2019

FDA rejects Sunovion"s experimental drug to treat Parkinson"s

The FDA has rejected a Parkinson's treatment from local drugmaker Sunovion Pharmaceuticals Inc., the company disclosed late Wednesday. Marlborough-based Sunovion, a subsidiary of the Japanese drug company Sumitomo Dainippon Pharma Co. Ltd., had asked.....»»

Category: topSource: bizjournalsJan 31st, 2019

This Orlando CRE firm"s employees like to work hard and play harder

Bishop Beale Duncan associates love to enjoy a companywide Beach Day, bungee jumping, a county fair-like dunk tank or one of the firm's many celebrations......»»

Category: topSource: bizjournalsJan 15th, 2019

Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza

Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery. .....»»

Category: worldSource: nytJan 11th, 2019

Lilly to buy Loxo Oncology for about $8 billion in cancer bet

Eli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 billion in cash, buying into a portfolio of targeted medicines to treat cancers caused by rare gene mutations......»»

Category: topSource: moneycentralJan 7th, 2019